<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144472">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01726985</url>
  </required_header>
  <id_info>
    <org_study_id>121368</org_study_id>
    <nct_id>NCT01726985</nct_id>
  </id_info>
  <brief_title>Model for Heart Failure ExAcerbation Reduction Trial</brief_title>
  <acronym>Model HEART</acronym>
  <official_title>Model for Heart Failure ExAcerbation Reduction Trial - &quot;Model HEART&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cleveland Clinic Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cleveland Clinic Florida</source>
  <oversight_info>
    <authority>United States: Cleveland Clinic Foundation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure is the leading cause of hospitalizations and readmissions in the United States
      and is a tremendous economic strain on our healthcare system.  There is currently, based on
      national averages, a 30% readmission rate and 10% mortality rate within 3 months of being
      hospitalized for heart failure. Retrospective studies have shown benefit to using biomarkers
      such as BNP to guide inpatient heart failure management. Our own CCF retrospective study
      showed that decreasing NT-ProBNP by 23%, making patients fluid negative by more than 1.3L,
      and discharging patients with serum sodium above 135 reduces readmission rates
      significantly. The purpose of this study is to prospectively use the above mentioned goals
      in the treatment of heart failure in order to reduce heart failure readmission and mortality
      rates.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Hospital Readmission for CHF</measure>
    <time_frame>up to  1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>CHF Mortality</measure>
    <time_frame>90 days, 180 days, 1 yr</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute on Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Patients hospitalized with CHF</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parameter Based Clinical Disposition</intervention_name>
    <description>Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:
NT-ProBNP reduction of &gt; 23% from peak value during admission
Fluid Reduction of &gt; 1.3L (orders for I/O q8h required)
Serum Sodium of &gt; 135 mmol/L the day of planned discharge</description>
    <arm_group_label>Patients hospitalized with CHF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients aged 18 and over hospitalized at Cleveland Clinic Florida with diagnosis of
        CHF.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have either Acute on Chronic Heart Failure or Chronic Heart Failure regardless
             of presenting/primary complaint

        To fulfill CHF Dx, MUST have 2+ of the following:

          -  Clinical: Dyspnea, orthopnea, PND, edema, S3, rales, improve w diuretics

          -  Radiographic: Pulm venous congestion, pleural effs, cardiomegaly

          -  Lab: NT pro BNP &gt; 1000

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlow B Hernandez, D.O.</last_name>
      <phone>954-659-5488</phone>
      <email>hernanm3@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Jose E Collado, M.D.</last_name>
      <phone>954-659-5488</phone>
      <email>colladj@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Marlow B Hernandez, D.O.,M.P.H.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose E Collado, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randall Schwartz, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergey Kachur, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Muniz, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nemer Dabage, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Gascon, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elsy V Navas, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gian Novaro, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Craig Asher, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darby Sider, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 14, 2012</lastchanged_date>
  <firstreceived_date>November 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
